Cambrex Expands Peptide Manufacturing Capabilities with 20% Facility Growth in Massachusetts
核心洞察
Cambrex's Snapdragon Chemistry (搜索) subsidiary has expanded its Waltham, Massachusetts API facility by 20% to enhance peptide therapy development and manufacturing capabilities.
The new GMP manufacturing suite features an ISO-7 cleanroom for preparative HPLC chromatography and lyophilization, along with specialized storage facilities for raw materials and products.
Snapdragon now offers comprehensive peptide manufacturing services from development to GMP production using solid-phase peptide synthesis (搜索), liquid-phase peptide synthesis (搜索), or hybrid approaches.
Cambrex, a leading global contract development and manufacturing organization (CDMO), has announced a significant expansion of its peptide manufacturing capabilities through its subsidiary Snapdragon Chemistry (搜索). The company has increased its active pharmaceutical ingredient (API) facility footprint in Waltham, Massachusetts by 20% to better support the growing demand for peptide therapy development and manufacturing.
Enhanced Manufacturing Infrastructure
The new GMP manufacturing suite represents a strategic investment in peptide production capabilities, featuring an ISO-7 cleanroom specifically designed for preparative HPLC chromatography and lyophilization processes. The expansion also includes dedicated cold storage facilities for raw materials and a comprehensive product storage suite, creating a complete manufacturing ecosystem for peptide therapies (搜索).
With this expansion, Snapdragon Chemistry (搜索) can now provide end-to-end support for peptide projects, spanning from initial development through GMP manufacturing. The facility offers multiple synthesis approaches, including solid-phase peptide synthesis (搜索) (SPPS), liquid-phase peptide synthesis (搜索) (LPPS), and hybrid methodologies to meet diverse client needs.
Innovative Three-Step Development Strategy
Dr. Eric Fang, General Manager at Snapdragon Chemistry (搜索), outlined the company's strategic approach to peptide development. "We designed this facility with a three-step strategy in mind for the development of peptide drug candidates," Fang explained. "We start with automated SPPS technology for proof-of-concept. In parallel, we optimize the process using LPPS technology to accelerate development and reduce manufacturing cost. We can then transfer the process to our large manufacturing facilities, such as Charles City, Iowa, to produce materials in traditional large batch reactors, significantly reducing the cost of those drugs."
Advanced Liquid-Phase Peptide Synthesis Technology
Snapdragon's proprietary LPPS technology represents a significant advancement in peptide manufacturing efficiency. Unlike traditional methods, this technology utilizes conventional API batch reactors and continuous flow processes, eliminating the dependency on specialized solid-phase reactors. The LPPS approach materially reduces solvent demand and minimizes the need for excess reagents compared to standard solid-state peptide synthesis processes.
Dr. Matt Bio, Chief Scientific Officer at Cambrex, emphasized the scalability advantages of this approach. "SPPS certainly has its place. We use it in early development to get to the clinic and to proof-of-concept quickly, but it's not a scalable solution if you want to supply a huge patient population," Bio stated. "We designed the LPPS process so that we can leverage all 1.4 million liters of capacity within Cambrex to deliver peptide therapies (搜索)."
Continued Investment in Complex Modalities
The expansion reflects Cambrex's broader commitment to advancing complex synthetic modalities. The company continues to invest in research and development across multiple areas, including further innovation in peptide manufacturing technologies and new research applications of artificial intelligence for optimizing oligonucleotide processes.
Snapdragon Chemistry (搜索), headquartered in Waltham, Massachusetts, employs over 70 professionals with strong connections to the local scientific community, including 31 PhD scientists on staff. The facility leverages state-of-the-art automation technology and proprietary equipment to address complex process and analytical development challenges in pharmaceutical manufacturing.